Trevena Inc (NASDAQ:TRVN) shares gapped down before the market opened on Tuesday . The stock had previously closed at $1.33, but opened at $1.41. Trevena shares last traded at $1.39, with a volume of 19750 shares.
TRVN has been the subject of several research reports. Zacks Investment Research upgraded Trevena from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Friday, January 18th. HC Wainwright restated a “hold” rating and issued a $1.25 target price on shares of Trevena in a research note on Thursday, March 14th. Finally, ValuEngine downgraded Trevena from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $4.69.
The company has a debt-to-equity ratio of 0.18, a current ratio of 3.58 and a quick ratio of 3.55. The company has a market capitalization of $130.22 million, a P/E ratio of -3.19 and a beta of 2.55.
Trevena (NASDAQ:TRVN) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. Equities analysts forecast that Trevena Inc will post -0.37 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. boosted its stake in Trevena by 142.9% in the 1st quarter. Advisor Group Inc. now owns 17,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 10,000 shares during the period. Two Sigma Advisers LP boosted its stake in Trevena by 35.3% in the 4th quarter. Two Sigma Advisers LP now owns 62,900 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 16,400 shares during the period. Alpine Global Management LLC bought a new stake in shares of Trevena during the 1st quarter valued at about $31,000. Northern Trust Corp boosted its position in shares of Trevena by 15.2% during the 1st quarter. Northern Trust Corp now owns 156,298 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 20,592 shares during the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in shares of Trevena during the 1st quarter valued at about $46,000. Institutional investors and hedge funds own 21.54% of the company’s stock.
Trevena Company Profile (NASDAQ:TRVN)
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.
Further Reading: Portfolio Manager
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.